Gyre Therapeutics (GYRE) Research & Development (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Research & Development data on file, last reported at $6.7 million in Q1 2026.

• Research & Development for Q1 2026 came in at $6.7 million, up 117.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.3 million (up 34.04% YoY), and the FY2025 annual result was $13.7 million, up 13.92% from the prior year.
• Research & Development climbed to $6.7 million in Q1 2026 per GYRE's latest filing, from $4.8 million in the prior quarter.
• Over five years, Research & Development peaked at $9.7 million in Q1 2022 and troughed at $803000.0 in Q3 2022.
• A 5-year average of $3.7 million and a median of $3.4 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2023: Research & Development sank 96.05% in 2022, then surged 274.72% in 2023.
• A 5-year view of Research & Development shows it stood at $4.3 million in 2022, then increased by 6.01% to $4.6 million in 2023, then retreated by 18.74% to $3.7 million in 2024, then climbed by 29.71% to $4.8 million in 2025, then surged by 39.94% to $6.7 million in 2026.
• Business Quant data shows GYRE's Research & Development at $6.7 million in Q1 2026, $4.8 million in Q4 2025, and $2.4 million in Q3 2025.